60 and older, any sex, with Hematologic Malignancies. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Retention RatePrimary· From consent until completion of the ACP intervention visit, usually within 1 week.
Retention rate is the percentage of consented patients who completed the ACP intervention visit. A retention rate of \>70% was considered feasible.
Retained - completed ACP intervention
Group
Value
95% CI
Advanced Care Planning
38
Not retained - didn't complete ACP intervention
Group
Value
95% CI
Advanced Care Planning
3
Advance Directive Completion - HCPSecondary· From baseline (pre-intervention) to 1 year post-intervention. The time interval is approximately 1 year.
Data on the patient's completion of scanned healthcare proxy form that was completed with their physician was collected via the electronic medical record. This is expressed as a percentage.
Baseline
Group
Value
95% CI
Advanced Care Planning
23
Advanced Care Planning
18
After ACP Intervention
Group
Value
95% CI
Advanced Care Planning
31
Advanced Care Planning
10
Advance Directive Completion - MOLSTSecondary· From baseline (pre-intervention) to 1 year post-intervention. The time interval is approximately 1 year.
Data on the patient's completion of scanned medical order for life sustaining treatment (MOLST) form that was completed with their clinician was collected via the electronic medical record. This is expressed as a percentage.
Baseline
Group
Value
95% CI
Advanced Care Planning
7
Advanced Care Planning
34
After ACP Intervention
Group
Value
95% CI
Advanced Care Planning
20
Advanced Care Planning
21
Sponsor's own description
This is a pilot study to assess the preliminary efficacy of an inpatient advance care planning intervention on outcomes in older patients with hematologic malignancies
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
Other recruiting trials for Hematologic Malignancies
Currently open trials in the same condition.
NCT04546945 — Aberrant Expression of CD56 in Patients With Hematologic Malignancies.
· recruiting
NCT06926595 — Allogeneic HSCT With Low-Dose Post-Transplant Cyclophosphamide for GVHD Prevention
· Phase 2
· recruiting
NCT07186192 — Digital Health Intervention for Self-Management and Telemonitoring in Chimeric Antigen Receptor (CAR-T) Therapy
· Phase 3
· recruiting
NCT07195916 — A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
· Phase 1
· recruiting
NCT07162038 — Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-
· Phase 1
· recruiting
Other University of Rochester trials
Trials by the same sponsor.
NCT07075965 — Calcium Channel Blocker in Myotonic Dystrophy Type 1
· Phase 1
· not yet recruiting
NCT07423104 — A Study of Cladribine, Low Dose Cytarabine, and Venetoclax in Treatment of Relapsed/Refractory or Secondary Acute Myeloi
· Phase 2
· not yet recruiting
NCT05744869 — SBAT for Health Equity
· NA
· not yet recruiting
NCT06052956 — Efficacy of Methylene Blue Photodynamic Therapy for Treatment of Deep Tissue Abscesses
· Phase 2
· not yet recruiting
NCT07032636 — Reducing Crises and Suicide Within the Idaho Army National Guard
· NA
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Rochester
Last refreshed: 31 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05433090.